Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

Dalhoff, A.; Schubert, Sabine

doi:10.1016/j.ijantimicag.2010.04.014

Cited by 12 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be due to higher usage of quinolones in hospital settings where the HA-MRSA prevalence is high resulting in selection of quinolone resistance [68][69][70]. In year 2008, the fluoroquinolone resistance among MRSA isolates implicated in acute bacterial skin and skin structure infections (ABSSSIs) in hospitals was at 70.3%.…”

Section: Quinolones Resistancementioning

confidence: 99%

Staphylococcus aureus: Overview of Bacteriology, Clinical Diseases, Epidemiology, Antibiotic Resistance and Therapeutic Approach

Gnanamani¹,

Periasamy²,

Paul‐Satyaseela³

2017

Frontiers in Staphylococcus Aureus

View full text Add to dashboard Cite

Staphylococcus aureus is an important human pathogen that causes wide range of infectious conditions both in nosocomial and community settings. The Gram-positive pathogen is armed with battery of virulence factors that facilitate to establish infections in the hosts. The organism is well known for its ability to acquire resistance to various antibiotic classes. The emergence and spread of methicillin-resistant S. aureus (MRSA) strains which are often multi-drug resistant in hospitals and subsequently in community resulted in significant mortality and morbidity. The epidemiology of MRSA has been evolving since its initial outbreak which necessitates a comprehensive medical approach to tackle this pathogen. Vancomycin has been the drug of choice for years but its utility was challenged by the emergence of resistance. In the last 10 years or so, newer anti-MRSA antibiotics were approved for clinical use. However, being notorious for developing antibiotic resistance, there is a continuous need for exploring novel anti-MRSA agents from various sources including plants and evaluation of non-antibiotic approaches.

show abstract

Section: Quinolones Resistancementioning

confidence: 99%

Staphylococcus aureus: Overview of Bacteriology, Clinical Diseases, Epidemiology, Antibiotic Resistance and Therapeutic Approach

Gnanamani¹,

Periasamy²,

Paul‐Satyaseela³

2017

Frontiers in Staphylococcus Aureus

View full text Add to dashboard Cite

show abstract

“…Some of the SCCmec elements contain additional genes for antibiotic resistance encoding for aminglycoside-, tetracycline-, and macrolide-lincosamide-streptogramin-resistance [319, 320]. Furthermore, HA-MRSA tended to develop fluoroquinolone resistance more frequently than MSSA [321, 322]. This phenomenon may be due to the fact that on the chromosomal map of the S. aureus genome the mecA gene is located between protein A and DNA gyrase genes.…”

Section: Fluoroquinolone Resistance Epidemiologymentioning

confidence: 99%

Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use

Dalhoff

2012

Interdisciplinary Perspectives on Infectious Diseases

Self Cite

293

211

View full text Add to dashboard Cite

This paper on the fluoroquinolone resistance epidemiology stratifies the data according to the different prescription patterns by either primary or tertiary caregivers and by indication. Global surveillance studies demonstrate that fluoroquinolone resistance rates increased in the past years in almost all bacterial species except S. pneumoniae and H. influenzae, causing community-acquired respiratory tract infections. However, 10 to 30% of these isolates harbored first-step mutations conferring low level fluoroquinolone resistance. Fluoroquinolone resistance increased in Enterobacteriaceae causing community acquired or healthcare associated urinary tract infections and intraabdominal infections, exceeding 50% in some parts of the world, particularly in Asia. One to two-thirds of Enterobacteriaceae producing extended spectrum β-lactamases were fluoroquinolone resistant too. Furthermore, fluoroquinolones select for methicillin resistance in Staphylococci. Neisseria gonorrhoeae acquired fluoroquinolone resistance rapidly; actual resistance rates are highly variable and can be as high as almost 100%, particularly in Asia, whereas resistance rates in Europe and North America range from <10% in rural areas to >30% in established sexual networks. In general, the continued increase in fluoroquinolone resistance affects patient management and necessitates changes in some guidelines, for example, treatment of urinary tract, intra-abdominal, skin and skin structure infections, and traveller's diarrhea, or even precludes the use in indications like sexually transmitted diseases and enteric fever.

show abstract

“…Ciprofloxacin is a better MRSA selector than levofloxacin. Aminoglycosides and tobramycin in particular are unlikely to be effective because the aadD gene, encoding 4=,4Љ-adenylyltransferase, conferring tobramycin resistance is present within SCCmec (255)(256)(257)(258). Aztreonam selects for aminoglycoside resistance in an MRSA background (259).…”

Section: Emergence Of Resistance In Pk/pd Studies and In Cf Patientsmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients

Dalhoff¹

2014

Clin Microbiol Rev

Self Cite

View full text Add to dashboard Cite

SUMMARY Bacteria adapt to growth in lungs of patients with cystic fibrosis (CF) by selection of heterogeneously resistant variants that are not detected by conventional susceptibility testing but are selected for rapidly during antibacterial treatment. Therefore, total bacterial counts and antibiotic susceptibilities are misleading indicators of infection and are not helpful as guides for therapy decisions or efficacy endpoints. High drug concentrations delivered by aerosol may maximize efficacy, as decreased drug susceptibilities of the pathogens are compensated for by high target site concentrations. However, reductions of the bacterial load in sputum and improvements in lung function were within the same ranges following aerosolized and conventional therapies. Furthermore, the use of conventional pharmacokinetic/pharmacodynamic (PK/PD) surrogates correlating pharmacokinetics in serum with clinical cure and presumed or proven eradication of the pathogen as a basis for PK/PD investigations in CF patients is irrelevant, as minimization of systemic exposure is one of the main objectives of aerosolized therapy; in addition, bacterial pathogens cannot be eradicated, and chronic infection cannot be cured. Consequently, conventional PK/PD surrogates are not applicable to CF patients. It is nonetheless obvious that systemic exposure of patients, with all its sequelae, is minimized and that the burden of oral treatment for CF patients suffering from chronic infections is reduced.

show abstract

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

Cited by 12 publications

References 34 publications

Staphylococcus aureus: Overview of Bacteriology, Clinical Diseases, Epidemiology, Antibiotic Resistance and Therapeutic Approach

Staphylococcus aureus: Overview of Bacteriology, Clinical Diseases, Epidemiology, Antibiotic Resistance and Therapeutic Approach

Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical Use

Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients

Contact Info

Product

Resources

About